The MAF Test®, developed by the IRB Barcelona and ICREA spin-off Inbiomotion, is now available to oncology and pathology professionals in South Korea and is estimated to benefit around 34,000 new patients each year.

This is the first time a product resulting from research at IRB Barcelona has reached patients in South Korea.

This pioneering test helps oncology professionals predict recurrence and survival rates in breast cancer patients, as well as their potential eligibility to receive treatment with bisphosphonates.

With its entry into South Korea, Inbiomotion reinforces the international projection of the MAF Test® and consolidates a distribution network that already covers Spain, Europe, Africa, and Asia.

The SEOM-GEICAM-SOLTI Clinical Guidelines for early-stage breast cancer recommend the use of the MAF Test® in their 2025 update.

Researchers have developed a technique that can identify errors caused by mutations linked to a range of genetic disorders, including forms of muscular dystrophy, Huntington’s disease and amyotrophic lateral sclerosis (ALS), which could accelerate accurate diagnosis of these conditions.

A new study from the University of Copenhagen maps a complex network of factors that may trap young adults in poor sleep patterns and mental distress. The research is already being used to target interventions for young people in a Danish municipality.